Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)

Francisco Cervantes; David M. Ross; Atanas Radinoff; Francesca Palandri; Alexandr Myasnikov; Alessandro M. Vannucchi; Pierre Zachee; Heinz Gisslinger; Norio Komatsu; Lynda Foltz; Francesco Mannelli; Francesco Passamonti; Geralyn Gilotti; Islam Sadek; Ranjan Tiwari; Evren Zor; Haifa Kathrin Al-Ali

doi:10.1038/s41375-021-01396-x

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)

Francisco Cervantes, David M. Ross, Atanas Radinoff, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Pierre Zachee, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti, Geralyn Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor, Haifa Kathrin Al-Ali

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

Original language	English
Pages (from-to)	3626
Number of pages	1
Journal	Leukemia
Volume	35
Issue number	12
Early online date	2 Sept 2021
DOIs	https://doi.org/10.1038/s41375-021-01396-x
Publication status	Published - Dec 2021
Externally published	Yes

Keywords

Chemotherapy
Myeloproliferative disease

Access to Document

10.1038/s41375-021-01396-xLicence: In Copyright

https://rdcu.be/dqUETLicence: In Copyright

Fingerprint

Dive into the research topics of 'Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)'. Together they form a unique fingerprint.

Cite this

Cervantes, F., Ross, D. M., Radinoff, A., Palandri, F., Myasnikov, A., Vannucchi, A. M., Zachee, P., Gisslinger, H., Komatsu, N., Foltz, L., Mannelli, F., Passamonti, F., Gilotti, G., Sadek, I., Tiwari, R., Zor, E., & Al-Ali, H. K. (2021). Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x). Leukemia, 35(12), 3626. https://doi.org/10.1038/s41375-021-01396-x

@article{d4480dc56a8747a68de96668d52883a1,

title = "Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)",

abstract = "Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.",

keywords = "Chemotherapy, Myeloproliferative disease",

author = "Francisco Cervantes and Ross, {David M.} and Atanas Radinoff and Francesca Palandri and Alexandr Myasnikov and Vannucchi, {Alessandro M.} and Pierre Zachee and Heinz Gisslinger and Norio Komatsu and Lynda Foltz and Francesco Mannelli and Francesco Passamonti and Geralyn Gilotti and Islam Sadek and Ranjan Tiwari and Evren Zor and Al-Ali, {Haifa Kathrin}",

year = "2021",

month = dec,

doi = "10.1038/s41375-021-01396-x",

language = "English",

volume = "35",

pages = "3626",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

Cervantes, F, Ross, DM, Radinoff, A, Palandri, F, Myasnikov, A, Vannucchi, AM, Zachee, P, Gisslinger, H, Komatsu, N, Foltz, L, Mannelli, F, Passamonti, F, Gilotti, G, Sadek, I, Tiwari, R, Zor, E & Al-Ali, HK 2021, 'Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)', Leukemia, vol. 35, no. 12, pp. 3626. https://doi.org/10.1038/s41375-021-01396-x

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x). / Cervantes, Francisco; Ross, David M.; Radinoff, Atanas et al.
In: Leukemia, Vol. 35, No. 12, 12.2021, p. 3626.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)

AU - Cervantes, Francisco

AU - Ross, David M.

AU - Radinoff, Atanas

AU - Palandri, Francesca

AU - Myasnikov, Alexandr

AU - Vannucchi, Alessandro M.

AU - Zachee, Pierre

AU - Gisslinger, Heinz

AU - Komatsu, Norio

AU - Foltz, Lynda

AU - Mannelli, Francesco

AU - Passamonti, Francesco

AU - Gilotti, Geralyn

AU - Sadek, Islam

AU - Tiwari, Ranjan

AU - Zor, Evren

AU - Al-Ali, Haifa Kathrin

PY - 2021/12

Y1 - 2021/12

N2 - Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

AB - Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

KW - Chemotherapy

KW - Myeloproliferative disease

UR - http://www.scopus.com/inward/record.url?scp=85114729790&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01396-x

DO - 10.1038/s41375-021-01396-x

M3 - Comment/debate

C2 - 34475521

AN - SCOPUS:85114729790

SN - 0887-6924

VL - 35

SP - 3626

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM et al. Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x). Leukemia. 2021 Dec;35(12):3626. Epub 2021 Sept 2. doi: 10.1038/s41375-021-01396-x

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study (Leukemia, (2021), 35, 12, (3455-3465), 10.1038/s41375-021-01261-x)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this